NCT06334133
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 52-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study
vTv Therapeutics·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Diabetes Mellitus, Type 1
- Drug/Device/Intervention
- Cadisegliatin 800 mg QD
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- vTv Therapeutics
Timeline & enrollment
- Phase
- Phase 3
- Start date
- May 01, 2024
- End date
- Mar 01, 2026
- Enrollment
- 150 participants
Primary outcome
Change in incidence of Level 2 or Level 3 hypoglycemia
Summary
This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus.
ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06334133
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06334133 through Pure Global AI's free database. This Phase 3 trial is sponsored by vTv Therapeutics and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.